A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. (Q34088250)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

phase I clinical trial

0 references

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

6

William A Denny

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Michael B Jameson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Danny Rischin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Mark Pegram

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

John Gutheil

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

William R Wilson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

10 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

791-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20012293%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-009-1188-1

15 January 2020

exact match

0 references

cites work

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-1188-1

The histological structure of some human lung cancers and the possible implications for radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-1188-1

Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-1188-1

The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-1188-1